Upgrade to SI Premium - Free Trial

Mizuho on Fate Therapeutics (FATE): 'setting up as a key year for the story'

March 24, 2026 3:04 PM
Mizuho analyst Mara Goldstein reiterated an Outperform rating and $8.00 price target on Fate Therapeutics (NASDAQ: FATE).The analyst comments "FATE ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments Hot Comments